NASDAQ : REVB
Revelation Biosciences, Inc. — Financial statements
Healthcare · Biotechnology · United States
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 6.09M | 5.01M | 4.43M | 4.51M | 5.49M | 5.04M |
| Research & Development | 5.18M | 4.06M | 3.55M | 4.15M | 5.38M | 6.91M |
| Operating Expenses | 11.27M | 9.07M | 7.98M | 8.66M | 10.86M | 11.95M |
| Operating Income | -11.27M | -9.07M | -7.98M | -8.66M | -10.86M | -11.95M |
| Other Non Operating Income (Expenses) | 518.72K | 157.16K | -7.06M | 8.54M | 34.96K | -36.35K |
| Pretax Income | -10.75M | -8.91M | -15.04M | -120.25K | -10.83M | -11.99M |
| Net Income | -10.75M | -8.91M | -15.04M | -120.25K | -10.83M | -11.99M |
| Preferred Dividends & Other Adjustments | 8.45M | 5.95M | ||||
| Net Income to Common | -19.20M | -14.87M | -15.04M | -120.25K | -10.83M | -11.99M |
| Shares Outstanding (Basic) | 330.05K | 88.68K | ||||
| Shares Outstanding (Diluted) | 330.05K | 88.68K | ||||
| EPS (Basic) | -58.18 | -167.62 | ||||
| EPS (Diluted) | -58.18 | -167.62 | ||||
| Free Cash Flow | -9.44M | -8.27M | -18.34M | -7.29M | -11.22M | -11.22M |
| Free Cash Flow Per Share | -28.60 | -93.25 | ||||
| EBITDA | -11.24M | -9.04M | -7.95M | -8.63M | -10.84M | -11.93M |
| D&A For EBITDA | 28.13K | 27.06K | 27.92K | 25.05K | 25.05K | 16.78K |
| EBIT | -11.27M | -9.07M | -7.98M | -8.66M | -10.86M | -11.95M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 11.48M | 10.70M | 6.50M | 11.99M | 5.25M | 1.27M |
| Cash & Short-Term Investments | 11.48M | 10.70M | 6.50M | 11.99M | 5.25M | 1.27M |
| Prepaid Expenses | 201.72K | 53.32K | 66.70K | 84.69K | 73.13K | 637.34K |
| Other Current Assets | 57.97K | 71.13K | 87.17K | |||
| Total Current Assets | 11.68M | 10.81M | 6.57M | 12.15M | 5.41M | 1.91M |
| Property, Plant & Equipment | 782.48K | 740.36K | 56.33K | 65.08K | 90.13K | 130.14K |
| Other Long-Term Assets | 30.94K | 30.94K | ||||
| Total Assets | 12.50M | 11.58M | 6.62M | 12.21M | 5.50M | 2.04M |
| Accounts Payable | 931.09K | 577.50K | 783.62K | 1.36M | 554.21K | 596.26K |
| Accrued Expenses | 759.94K | 1.40M | 1.13M | 1.15M | 985.50K | 1.53M |
| Current Portion of Leases | 189.37K | 23.01K | 16.75K | |||
| Other Current Liabilities | 3.05M | 2.91M | ||||
| Total Current Liabilities | 1.88M | 2.00M | 1.91M | 5.56M | 4.45M | 2.14M |
| Long-Term Leases | 550.55K | 723.77K | ||||
| Total Liabilities | 2.43M | 2.72M | 1.91M | 5.56M | 4.45M | 2.14M |
| Common Stock | 3.91K | 1.58K | 44.00 | 16.00 | 77.00 | 282.00 |
| Additional Paid-In Capital | 65.81M | 58.28M | 45.21M | 32.11M | 26.40M | 14.42M |
| Retained Earnings | -55.75M | -49.42M | -40.51M | -25.47M | -25.35M | -14.52M |
| Total Common Equity | 10.07M | 8.86M | 4.71M | 6.65M | 1.05M | -99.47K |
| Shareholders' Equity | 10.07M | 8.86M | 4.71M | 6.65M | 1.05M | -99.47K |
| Total Liabilities & Equity | 12.50M | 11.58M | 6.62M | 12.21M | 5.50M | 2.04M |
| Total Debt | 739.92K | 746.78K | 16.75K | |||
| Net Cash (Debt) | 10.74M | 9.95M | 6.50M | 11.99M | 5.25M | 1.26M |
| Net Cash Per Share | 32.55 | 112.24 | ||||
| Filing Date Shares Outstanding | 569.06K | 531.49K | 10.78K | |||
| Total Common Shares Outstanding | 558.35K | 226.28K | ||||
| Working Capital | 9.80M | 8.81M | 4.65M | 6.58M | 962.32K | -229.61K |
| Book Value Per Share | 18.03 | 39.16 | ||||
| Tangible Book Value | 10.07M | 8.86M | 4.71M | 6.65M | 1.05M | -99.47K |
| Tangible Book Value Per Share | 18.03 | 39.16 | ||||
| Machinery | 286.54K | 117.06K | 151.13K | 131.96K | 131.96K | 131.96K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -10.75M | -8.91M | -15.04M | -120.25K | -10.83M | -11.99M |
| Depreciation & Amortization | 28.13K | 27.06K | 27.92K | 25.05K | 25.05K | 16.78K |
| Loss (Gain) From Sale of Assets | 4.49K | 11.21K | ||||
| Stock-Based Compensation | 1.24M | 595.37K | 193.85K | 155.72K | 301.12K | 470.88K |
| Other Operating Activities | 129.78K | 16.47K | -81.44K | -8.33M | 14.96K | 52.38K |
| Change in Accounts Payable | 102.20K | -206.12K | -576.28K | 749.66K | -666.04K | -269.64K |
| Change in Other Net Operating Assets | -85.37K | 200.08K | -2.85M | 232.47K | -64.93K | 625.86K |
| Operating Cash Flow | -9.33M | -8.27M | -18.32M | -7.29M | -11.22M | -11.09M |
| Capital Expenditures | -111.51K | -19.17K | -131.96K | |||
| Investing Cash Flow | -111.51K | -19.17K | -131.96K | |||
| Short-Term Debt Issued | 2.50M | |||||
| Total Debt Issued | 2.50M | |||||
| Short-Term Debt Repaid | -2.50M | |||||
| Long-Term Debt Repaid | -796.88K | |||||
| Total Debt Repaid | -3.30M | |||||
| Net Debt Issued (Repaid) | -796.88K | |||||
| Issuance of Common Stock | 15.75M | 12.47M | 12.85M | 14.03M | 11.72M | 600.00K |
| Repurchase of Common Stock | -7.65M | |||||
| Other Financing Activities | 11.92M | |||||
| Financing Cash Flow | 15.75M | 12.47M | 12.85M | 14.03M | 15.20M | 8.00M |
| Net Cash Flow | 6.31M | 4.20M | -5.49M | 6.74M | 3.98M | -3.22M |
| Free Cash Flow | -9.44M | -8.27M | -18.34M | -7.29M | -11.22M | -11.22M |
| Free Cash Flow Per Share | -28.60 | -93.25 | ||||
| Levered Free Cash Flow | -5.78M | -5.03M | -8.34M | -4.11M | -3.66M | -6.71M |
| Unlevered Free Cash Flow | -5.78M | -5.03M | -8.34M | -4.11M | -3.66M | -6.71M |
| Change in Working Capital | 16.83K | -6.04K | -3.42M | 982.13K | -730.97K | 356.22K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 2.30M | 4.74M | 3.85M | 3.15M | 4.29M | 57.58M |
| Enterprise Value | -8.44M | -7.97M | -2.69M | -10.85M | -1.90M | 60.96M |
| Last Close Price | 4.03 | 22.39 | 619.58 | 20,188.21 | 268,275.47 | 14,394,581.00 |
| PB Ratio | 0.22 | 0.54 | 0.82 | 0.47 | 4.08 | -578.85 |
| P/TBV Ratio | 0.22 | 0.54 | 0.82 | 0.47 | 4.08 | |
| Debt / Equity Ratio | 0.07 | 0.08 | -0.17 | |||
| Net Debt / Equity Ratio | -1.07 | -1.12 | -1.38 | -1.80 | -4.99 | 12.65 |
| Net Debt / EBITDA Ratio | 0.96 | 1.10 | 0.82 | 1.39 | 0.48 | 0.10 |
| Net Debt / FCF Ratio | 1.14 | 1.20 | 0.35 | 1.65 | 0.47 | 0.11 |
| Quick Ratio | 6.11 | 5.36 | 3.40 | 2.15 | 1.18 | 0.59 |
| Current Ratio | 6.21 | 5.41 | 3.43 | 2.18 | 1.22 | 0.89 |
| Return on Equity (ROE) | -154.77% | -131.38% | -264.85% | -3.12% | -2,272.77% | -723.81% |
| Return on Assets (ROA) | -78.73% | -62.28% | -52.93% | -61.08% | -179.98% | -224.21% |
| Return on Capital Employed (ROCE) | -106.10% | -94.60% | -169.40% | -130.20% | -1,032.30% | 12,014.20% |
| Earnings Yield | -1,436.52% | -188.13% | -390.41% | -3.82% | -252.29% | -20.82% |
| FCF Yield | -425.33% | -174.53% | -476.13% | -231.36% | -261.38% | -19.49% |